...
首页> 外文期刊>Current computer-aided drug design >Identification of N-Benzylated Indole Mannich Bases as Potential Anti TB Agents by Using Computational Studies and Molecular Hybridization Technique
【24h】

Identification of N-Benzylated Indole Mannich Bases as Potential Anti TB Agents by Using Computational Studies and Molecular Hybridization Technique

机译:通过使用计算研究和分子杂交技术鉴定N-苄基化吲哚碱基作为潜在的抗TB试剂

获取原文
获取原文并翻译 | 示例

摘要

Introduction: Morbidity and mortality due to tuberculosis are rising steadily. Despite havingefficient drugs and treatment protocols, microbial drug resistance often leads to treatment failure. Effortsto bring novel drugs to combat this menace are hampered by several issues including problems ingaining industry support, motivation and ethical issues clinical trials. Bedaquiline and Delaminid arethe only novel drugs approved in the last three decades for treating TB. A few more molecules anddrug combinations are still in clinical trials. One such drug is the BM212, a potent anti-TB agent whichacts by a novel mechanism of action.Methods: In the present study, we used virtual screening method with a combination of molecular hybridizationtechnique to design N-benzylated Indole Mannich bases as potent anti-TB agent based onBM212 pharmacophore. The library of designed molecules was prepared and screened using BM212model. The top 5 ‘hit’ molecules were selected (with good TC score >1.15), synthesized and screenedfor anti TB activity by MABA assay method.Results and Conclusion: All the compounds showed excellent anti TB activity, of which 4 compoundshave shown MIC ≤12.5 μg/mL. Our protocol could help in the designing of newer anti-TB agents withbetter bioactivity profile.
机译:介绍:肺结核引起的发病率和死亡率稳步上升。尽管药物和治疗方案有特异性,但微生物耐药性通常导致治疗失败。努力将新的药物打击这种威胁,受到几个问题的阻碍,包括培养行业支持,动机和伦理问题的问题。 Bedaquiline和Delaminid只有在过去三十年中批准的新型药物治疗结核病。还有一些分子和滴剂组合仍在临床试验中。一种这样的药物是BM212,一种有效的抗TB剂,通过新的动作机制。方法:在本研究中,我们使用虚拟筛选方法与分子杂交技术的组合设计N-苄基化的Indole Mannich碱基作为有效抗体-TB基于ANBM212 Pharmacophore。使用BM212Model制备并筛选设计的分子库。选择前5'命中的分子(具有良好的TC得分> 1.15),通过MABA测定方法合成并筛选抗TB活性。结果和结论:所有化合物显示出优异的抗TB活性,其中4个化合物显示MIC≤12.5 μg/ ml。我们的协议可以帮助设计较新的抗TB代理商与生物活性概况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号